Targeting KLRD1: A Promising Drug Pathway (G3824)

Target Name: KLRD1

NCBI ID: G3824

KLRD1

Targeting KLRD1: A Promising Drug Pathway

KLRD1 (KLRD1 variant 2) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of theklion family of proteins, which are characterized by the presence of a specific domain called the N-terminal alpha-helix.

KLRD1 has been shown to play a role in various physiological processes in the body, including cell signaling, inflammation, and stress resistance. It is also involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Due to its involvement in so many different processes in the body, KLRD1 has become a promising drug target for a variety of diseases. Researchers are currently exploring the potential of using small molecules, antibodies, and other therapeutic approaches to target KLRD1 in order to treat a range of conditions.

One approach that is being explored for targeting KLRD1 is the use of small molecules. Small molecules are chemical compounds that can interact with specific proteins and cause them to change their structure or activity. By using small molecules to modify the activity of KLRD1, researchers hope to develop drugs that can be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach that is being explored for targeting KLRD1 is the use of antibodies. Antibodies are proteins that are produced by the immune system in response to the presence of a specific foreign substance in the body. By using antibodies to target KLRD1, researchers hope to develop drugs that can be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to these approaches, researchers are also exploring the use of other therapeutic approaches, such as genetic modification and gene therapy, to target KLRD1. By modifying the genetic code of KLRD1 or using genes to deliver therapeutic molecules directly to KLRD1, researchers hope to develop drugs that can be used to treat a variety of conditions.

Overall, KLRD1 is a protein that has the potential to be a drug target for a variety of diseases. As research continues to advance, it is likely that new approaches will be discovered that will further our understanding of the role of KLRD1 in the body and the development of effective treatments for a range of conditions.

Protein Name: Killer Cell Lectin Like Receptor D1

Functions: Immune receptor involved in self-nonself discrimination. In complex with KLRC1 or KLRC2 on cytotoxic and regulatory lymphocyte subsets, recognizes non-classical major histocompatibility (MHC) class Ib molecule HLA-E loaded with self-peptides derived from the signal sequence of classical MHC class Ia and non-classical MHC class Ib molecules (PubMed:9486650, PubMed:10023772, PubMed:18083576, PubMed:18064301, PubMed:9754572). Enables cytotoxic cells to monitor the expression of MHC class I molecules in healthy cells and to tolerate self (PubMed:9430220, PubMed:12387742, PubMed:18064301). Primarily functions as a ligand binding subunit as it lacks the capacity to signal

The "KLRD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLRD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets